Skip to content
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression. Nat Immunol. 2026 Jun;27(6):1104-1118. doi: 10.1038/s41590-026-02529-z. Epub 2026 May 18.
- A proteome-wide atlas of humoral immunity to Mycobacterium tuberculosisacross the spectrum of disease. Khan MZ, Irvine EB, Cizmeci D, Davies LRL, Randall AZ, Pablo J, Vidal SJ, Lasrado N, Darrah PA, Hsiao JC, Mann C, Nair S, Grace PS, Fontana L, Juelg B, Barouch DH, Restrepo BI, Roederer M, Seder RA, Wallis RS, Churchyard G, Stein CM, Boom WH, Campo JJ, Alter G. Front Immunol. 2026 Jun 3;17:1810894. doi: 10.3389/fimmu.2026.1810894.
- Genetically diverse CC and DO mouse models enable comprehensive assessments of novel tuberculosis vaccines. Lai R, Kurtz SL, Gould V, Tran A, Afkhami S, Brosch R, Lindestam Arlehamn CS, Xing Z, Elkins KL, Behar SM. NPJ Vaccines. 2026 Jun 5. doi: 10.1038/s41541-026-01498-6. Epub ahead of print.
- Inclusion of young adolescents in policy development for new tuberculosis vaccines. Hatherill M, Clark RA, Martinez L, Fiore-Gartland AL, Garcia-Basteiro AL, Churchyard GJ, Rangaka MX, Behr MA, Evans T, Mave V, Hill PC, Hanekom WA, Cobelens F, White RG; Pediatric TB Contact Studies Consortium. Lancet Glob Health. 2026 Jun 8:S2214-109X(26)00017-3. doi: 10.1016/S2214-109X(26)00017-3. Epub ahead of print.
- The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design. Dagnew AF, Schmidt AC, Cinar A, Garcia-Basteiro AL, Noble R, Pelzer PT, Churchyard GJ, Hatherill M, White RG, Cobelens F. 2026 Jun 10;88:128822. doi: 10.1016/j.vaccine.2026.128822. Epub ahead of print.
- mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models. Agrawal N, Ates LS, Schille SA, Chaturvedi A, Vogt J, Vukovic N, Dulberger CL, Vogel AB, Diekmann J, Diken M, Şahin U. Nat Immunol. 2026 Jun 12. doi: 10.1038/s41590-026-02545-z
- Immortal genome assumption significantly underestimates replication and death rates of Mycobacterium tuberculosisin mice and monkeys. Friesen AD, Ganusov VV. Microbiol Spectr. 2026 Jun 15:e0302025. doi: 10.1128/spectrum.03020-25. Epub ahead of print.
- Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge model. Li S, Morrison H, Duta M, Marshall JL, Harris SA, He W, Ateere A, Nassanga B, Satti I, McShane H. Cell Rep Med. 2026 Jun 16;7(6):102830. doi: 10.1016/j.xcrm.2026.102830. Epub 2026 May 21.
- Booster vaccine reduces BCG-primed mice’s protection against primary Mycobacterium tuberculosis infection by raising IL-10 levels. Lei Q, Lin X, Yao Z, Fu H, Wang Y, Yuan Y, Ouyang Q, Xu X, Cao J, Gan M, Fan X. Vaccine. 2026 Jun 16;88:128841. doi: 10.1016/j.vaccine.2026.128841. Epub ahead of print.
- Whole β-glucan particles modulate BCG-induced macrophage and CD4+T-cell responses via the Dectin-1-JAK1/STAT1 pathway. Cao Y, Qu H, Tian Q, Sun S, Zhang W, Fang D, Chen P, Zhao C, Zhang XL, Pan Q, Luo F, Liu M. Commun Biol. 2026 Jun 17. doi: 10.1038/s42003-026-10492-6. Epub ahead of print. PMID: 42310217.
- In silico comparison of the differential proteome produced by the tuberculosis vaccine candidate BCGΔBCG1419c and its parental BCG strain cultured as biofilms or planktonic cells. Flores-Valdez MA, Velázquez-Fernández JB, Vallejo-Cardona AA, Aceves-Sánchez MJ, Rodríguez-Campos J. Vaccine. 2026 Jun 18;88:128855. doi: 10.1016/j.vaccine.2026.128855. Epub ahead of print.
- Advancing national preparedness for the introduction of novel tuberculosis vaccines in South Africa: policy, evidence, and system readiness insights from a national workshop. Ndjeka N, Subrayen P, Hanekom WA, Jassat W, Luabeya AKK, Mkhondo N, Muloiwa R, Tisile P, Ntshiqa T, Boffa J, Giersing B. 2026 Jun 20;86:128755. doi: 10.1016/j.vaccine.2026.128755. Epub 2026 May 26.
- Targeted delivery of the BCG vaccine to dendritic cells improves protective efficacy against Mycobacterium tuberculosis. Counoupas C, Nisa A, Baker L, Pinto R, Bhattacharyya N, Demangel C, Britton WJ, Triccas JA. 2026 Jun 20;86:128753. doi: 10.1016/j.vaccine.2026.128753. Epub 2026 May 22.
- Airway immune signatures of protection and disease progression in recent human tuberculosis household contacts. Branchett WJ, Kim JW, Shields J, Chakravarty P, Lee J, Novsarka I, Slawinski H, Wilkinson KA, Wilkinson RJ, Kamil A, Verma R, Haldar P, O’Garra A. Nat Immunol. 2026 Jun 24. doi: 10.1038/s41590-026-02544-0. Epub ahead of print.
- Replication-deficient Adenovirus 5 Serotypes Induce Type I Interferon and enhance BCG-mediated Immune Response in Co-infected Murine Macrophages. Vecchio JA, Schorey JS. bioRxiv [Preprint]. 2026 Jun 24:2026.06.24.734229. doi: 10.64898/2026.06.24.734229.
- Antigen-Pulsed Dendritic Cell-Derived Dexosomes Induce a Robust Th1-Biased Antigen-Specific Humoral and Cellular Immunity in Mice against Latent Mycobacterium tuberculosisAntigen Rv2626c. Naz S, Dharani B, Ahmed F, Singh S, Srinivas D, Jagadeb M, Kanaparthi KJ, Ahmad S, Khan N, Banerjee S. ACS Infect Dis. 2026 Jun 25. doi: 10.1021/acsinfecdis.5c01111. Epub ahead of print.
- Computational design and immunoinformatic validation of a multistage mRNA vaccine candidate against Mycobacterium tuberculosis. Sharma M, Bhatt P, Singh M, Lokhande KB, Asthana S, Sharma M, Sharma S. In Silico Pharmacol. 2026 Jun 20;14(2):167. doi: 10.1007/s40203-026-00675-8.
- Antigen-Pulsed Dendritic Cell-Derived Dexosomes Induce a Robust Th1-Biased Antigen-Specific Humoral and Cellular Immunity in Mice against Latent Mycobacterium tuberculosisAntigen Rv2626c. Naz S, Dharani B, Ahmed F, Singh S, Srinivas D, Jagadeb M, Kanaparthi KJ, Ahmad S, Khan N, Banerjee S. ACS Infect Dis. 2026 Jun 25. doi: 10.1021/acsinfecdis.5c01111. Epub ahead of print.
- Comprehensive CyTOF and lipidomic analysis of splenic immune and serum lipid responses to BCG vaccination and H37Rv challenge in BALB/c mice. Van-Tilbeurgh M, Yang W, Lopez EM, Gallouët AS, Dagg B, Goulding S, Keeble J, Ho MM, Harms A, Grand RL, Khatri B. Sci Rep. 2026 Jun 26. doi: 10.1038/s41598-026-58623-7. Epub ahead of print.
- Impaired IFNγ responsiveness of monocyte-derived lung cells limits immunity to Mycobacterium tuberculosis. Zheng W, Limberis JD, Howard ZP, Mohapatra A, Takagi E, Ernst JD. Nat Commun. 2026 Jun 30. doi: 10.1038/s41467-026-75096-4. Epub ahead of print. PMID: 42373669.
- A systematic review of the determinants of vaccine hesitancy in the UK: Implications for future TB vaccine adoption. Kennard A, Kılıç A, Alsugeir D, Hamada Y, Rangaka MX. BMC Public Health. 2026 Jun 30. doi: 10.1186/s12889-026-28299-9. Epub ahead of print.
- Prophylactic and post-exposure efficacy of a Pichinde virus vector-based tuberculosis vaccine. Cain M, Block AM, Huang Q, Kirk NM, Murphy H, Harris MC, Ly H, Tischler AD, Liang Y. Front Immunol. 2026 Jun 30;17:1861052. doi: 10.3389/fimmu.2026.1861052.
